Page 4 - பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பாலியல் மற்றும் இனப்பெருக்கம் ஆரோக்கியம் Today - Breaking & Trending Today

No longer an outlier: New York ends commercial surrogacy ban

ABC News
Turn on desktop notifications for breaking stories about interest?
OffOn
No longer an outlier: New York ends commercial surrogacy ban
New York s longstanding ban on commercial surrogate pregnancy is about to end nine years after a bill to rescind it was first introduced
By DAVID CRARY AP National Writer
February 14, 2021, 6:34 PM
• 5 min read
The Associated Press
New York State Senator Brad Hoylman, left, with his husband David Sigal, right, pose with their daughters Lucy Hoylman-Sigal, 3, left, and Silvia Hoylman-Sigal, 10, both born through surrogacy, Saturday Feb. 6, 2021, in New York. Sen. Hoylman is the lead sponsor of a New York State law taking effect on Feb. 15 that legalizes commercial surrogacy. (AP Photo/Bebeto Matthews) ....

New York , United States , White Plains , Leah Marx , Andrew Kabatchnick , Brad Hoylman , Parham Zar , Asemblywoman Amy Paulin , David Sigal , Andrew Cuomo , Gloria Steinem , Vicki Ferrara , York Senate , Egg Donor Surrogacy Institute In Beverly Hills , Roman Catholic Church , New York Senate , Egg Donor , Surrogacy Institute , Worldwide Surrogacy , General News , Government And Politics , Pregnancy And Childbirth , Sexual And Reproductive Health , Women X27s Health , Gays And Lesbians , Surrogate Pregnancy ,

The Innovative Prosthetic Urology Portfolio From Rigicon Receives Marketing Approval in Australia

Press release content from Newswire. The AP news staff was not involved in its creation.
The Innovative Prosthetic Urology Portfolio From Rigicon Receives Marketing Approval in Australia
February 12, 2021 GMT
Rigicon is the manufacturer of innovative prosthetic urology devices.
RONKONKOMA, N.Y. - February 11, 2021 - ( Newswire.com )
Rigicon Inc., with its global headquarters in NY, USA, announces that their innovative prosthetic urology portfolio received marketing approval from Australia (Australian Government Department of Health Therapeutic Goods Administration).
The following implant options from Rigicon are now available for specialized surgeons and patients in Australia:
Infla10® Inflatable Penile Prosthesis Models
Rigi10™ Malleable Penile Prosthesis ....

United States , European Association Of Urology , Urological Society Of Australia , Rigicon Inc , American Urological Association , Australian Government Department , Health Therapeutic Goods Administration , Inflatable Penile Prosthesis Models , Malleable Penile , Artificial Urinary Sphincter , Testicular Prosthesis , Australian Economy , Erectile Dysfunction , Urinary Incontinence , Urological Society , New Zealand , European Association , Inflatable Penile Prosthesis , Anatomical Expansion , Malleable Penile Prosthesis , Inflatable Penile Prostheses Models , Artificial Urinary Sphincter Systems , Testicular Prosthesis Models , Release Service , Marketing And Advertising , Corporate News ,

Global Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

United Kingdom , Laura Wood , E St Office Hours Call , Merck Co Gardasil , Office Hours Call , Merck Co , Human Papillomavirus , Topics Covered , Approvals Boost Opdivo And Gardasil , Senior Press , Free Call , Hours Call , Business Wire , Public Health , Products And Services , Drug Approvals , Product Approvals , Hpv Infections , Sexually Transmitted Diseases , Sexual And Reproductive Health , Greater China , Pharmaceutical Manufacturing , Health Care Industry , New Products And Services , Medical Research , East Asia ,

Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers

Press release content from Business Wire. The AP news staff was not involved in its creation.
Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers
February 11, 2021 GMT
Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines (Photo: Business Wire)
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced a research collaboration with Dana-Farber Cancer Institute to advance discovery and clinical development in human papillomavirus-positive (HPV+) oropharyngeal (head and neck) cancers. Through this collaboration, Dana-Farber and Repertoire aim to identify novel tumor antigen targets relevant to HPV+ head and neck tumors that will be used to inform the development of novel therapeutic cand ....

United Kingdom , Dana Farber Cancer Institute , United States , Ann Marie Egloff , Glenn Hanna , Carlo Tanzi , Lindsayg Deefholts , Sarah Nikiforow , Anthony Coyle , Ravindra Uppaluri , Department Of Surgery , Immune Medicines , Repertoire Immune Medicines , Business Wire , Rare Head , Neck Cancers , Neck Surgical Oncology , Lead Investigator , Medical Oncology , Study Identifier Number , Media Contact , Products And Services , Product Testing , Diagnosis And Treatment , Hpv Infections , Sexually Transmitted Diseases ,

Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal .
Myovant Sciences, Inc.February 11, 2021 GMT
ORGOVYX™ (relugolix) approved by the
U.S. Food and Drug Administration (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021
Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in oncology and relugolix combination tablet in women’s health in the U.S. and Canada ....

New York , United States , City Of , United Kingdom , Sumitomo Dainippon Pharma , David Marek , Albert Liao , Bryan Crowe , Endometriosis Special Interest Group , Dainippon Pharmaceutical Co Ltd , European Union , Virtual Congress , American Society For Reproductive Medicine , Canada The Co , European Commission , Drug Administration , Myovant Sciences , Gedeon Richter , Exchange Commission , Myovant Sciences Ltd , Corporate Communications , Myovant Sciences Inc , European Medicines Agency , Scientific Congress Prize Paper Session , Sumitomo Dainippon Pharma Co Ltd , Sumitomo Pharmaceuticals Co Ltd ,